LOS ANGELES-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, delivered yesterday the keynote address at the 7th International Stem Cell Conference, a leading international stem cell conference held October 29-30th in Pittsburgh. The conference featured speakers and presenters from leading stem cell companies and academic researchers. Dr. Lanza was joined as a featured presenter by James F. Battey, Jr., M.D., Ph.D., Director - National Institute on Deafness and Other Communication Disorders.
Dr. Lanza discussed in his address Advanced Cell Technology's new technologies to address immune tolerance issues that are increasingly a focus of the stem cell industry, along with the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support.
Recently, Advanced Cell Technology announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I (b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
For more information, visit "www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
Andrew Hellman, 212-732-4300